ライフサイエンスコーパス: schizoaffective disorder

1 spectrum disorders (mostly schizophrenia and schizoaffective disorder).

2 spectrum disorders (mostly schizophrenia and schizoaffective disorder).

3 and cognitive functions in schizophrenia and schizoaffective disorder.

4 asive nicotinic effects in schizophrenia and schizoaffective disorder.

5 ican American probands with schizophrenia or schizoaffective disorder.

6 r predisposition genes for schizophrenia and schizoaffective disorder.

7 e treatment of early-onset schizophrenia and schizoaffective disorder.

8 e for treating early-onset schizophrenia and schizoaffective disorder.

9 olescents with early-onset schizophrenia and schizoaffective disorder.

10 otics to treat early-onset schizophrenia and schizoaffective disorder.

11 up (68% of survivors); 175 had schizophrenia/schizoaffective disorder.

12 tpatients with diagnoses of schizophrenia or schizoaffective disorder.

13 age and older patients with schizophrenia or schizoaffective disorder.

14 ficacy in the treatment of schizophrenia and schizoaffective disorder.

15 e intron 1/exon 2 region in individuals with schizoaffective disorder.

16 acutely ill inpatients with schizophrenia or schizoaffective disorder.

17 tion of the exon 9 missense allele Phe607 in schizoaffective disorder.

18 patients with diagnoses of schizophrenia or schizoaffective disorder.

19 ent of the first episode of schizophrenia or schizoaffective disorder.

20 with acute exacerbation of schizophrenia or schizoaffective disorder.

21 e and negative symptoms in schizophrenia and schizoaffective disorder.

22 nt of patients with chronic schizophrenia or schizoaffective disorder.

23 f relapse in patients with schizophrenia and schizoaffective disorder.

24 dividuals with recent-onset schizophrenia or schizoaffective disorder.

25 cognition in patients with schizophrenia or schizoaffective disorder.

26 ords of 82 outpatients with schizophrenia or schizoaffective disorder.

27 ponse to a first episode of schizophrenia or schizoaffective disorder.

28 ume was found in patients with schizophrenia/schizoaffective disorder.

29 ry from a first episode of schizophrenia and schizoaffective disorder.

30 a major depressive episode or diagnosed with schizoaffective disorder.

31 behavior in patients with schizophrenia and schizoaffective disorder.

32 th a DSM-III-R diagnosis of schizophrenia or schizoaffective disorder.

33 ive-compulsive disorder and schizophrenia or schizoaffective disorder.

34 with a primary diagnosis of schizophrenia or schizoaffective disorder.

35 rge among 151 patients with schizophrenia or schizoaffective disorder.

36 42 drug-free patients with schizophrenia or schizoaffective disorder.

37 percentage of patients with schizophrenia or schizoaffective disorder.

38 disorder and 38% of the treatments used for schizoaffective disorder.

39 ospective trial for patients with bipolar or schizoaffective disorder.

40 pelinian patients met DSM-III-R criteria for schizoaffective disorder.

41 patients had a diagnosis of schizophrenia or schizoaffective disorder.

42 sfunction in patients with schizophrenia and schizoaffective disorder.

43 ressive disorder (MDD), bipolar disorder, or schizoaffective disorder.

44 years of age or older with schizophrenia or schizoaffective disorder.

45 he abnormalities were similar between SZ and schizoaffective disorder.

46 ht outpatients with chronic schizophrenia or schizoaffective disorder.

47 h analysis of 4084 samples with BPAD, SZ, or schizoaffective disorder.

48 hotic disorders, including schizophrenia and schizoaffective disorders.

49 d group of 21 subjects with schizophrenia or schizoaffective disorder, 11 subjects with schizotypal p

50 randomization, 58.1% had schizophrenia or a schizoaffective disorder, 22.0% had bipolar disorder, an

51 ducted in 980 patients with schizophrenia or schizoaffective disorder, 26.8% of whom were refractory

52 reviously reported): 19 patients with SCZ or schizoaffective disorder, 30 unaffected first-degree rel

53 ere psychosis not otherwise specified (44%), schizoaffective disorder (36%), and brief psychosis (27%

54 g pairs with a diagnosis of schizophrenia or schizoaffective disorder, 396 highly polymorphic markers

55 ohort, 4310 developed bipolar disorder; 784, schizoaffective disorder; 4823, schizophrenia; and 5013,

56 .5% met DSM-IV criteria for schizophrenia or schizoaffective disorder; 55.8%, for major affective dis

57 comprising 42 patients with schizophrenia or schizoaffective disorder, 57 of their unaffected first-d

58 ence; 64 men with DSM-III-R schizophrenia or schizoaffective disorder; 62 men with Research Diagnosti

59 a (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to

60 samples (528 UK patients with schizophrenia/schizoaffective disorder; 921 German participants includ

61 s: (1) 170 individuals with schizophrenia or schizoaffective disorder and (2) 84 patients with broad

62 A total of 18 treatment studies of schizoaffective disorder and 15 of schizophrenia with mo

63 out including 10,925 cases with BPAD, SZ, or schizoaffective disorder and 16,747 controls.

64 Eighteen individuals with schizophrenia or schizoaffective disorder and 19 healthy control particip

65 nsisted of 23 patients with schizophrenia or schizoaffective disorder and 19 non-psychiatric voluntee

66 nts in the first episode of schizophrenia or schizoaffective disorder and 22 healthy comparison subje

67 Twenty-seven patients with schizophrenia or schizoaffective disorder and 23 healthy controls.

68 In 24 patients with schizophrenia or schizoaffective disorder and 25 healthy comparison subje

69 with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder and 26 healthy volunteers parti

70 ata for 3,945 subjects with schizophrenia or schizoaffective disorder and 3,611 screened comparison s

71 tudied 127 outpatients with schizophrenia or schizoaffective disorder and 30 healthy comparison subje

72 relates in 33 patients with schizophrenia or schizoaffective disorder and 31 healthy comparison subje

73 Forty-four patients with schizophrenia or schizoaffective disorder and 34 healthy comparison subje

74 ged and older patients with schizophrenia or schizoaffective disorder and 38 normal comparison subjec

75 essed in 149 consumers with schizophrenia or schizoaffective disorder and 50 healthy control subjects

76 ort of 524 individuals with schizophrenia or schizoaffective disorder and 573 control subjects.

77 ction from 62 subjects with schizophrenia or schizoaffective disorder and 62 matched healthy comparis

78 a subset of 59 people with schizophrenia or schizoaffective disorder and 65 healthy controls, and pr

79 dication-free patients with schizophrenia or schizoaffective disorder and 74 healthy comparison indiv

80 btained from 96 people with schizophrenia or schizoaffective disorder and 83 healthy controls.

81 , 18-51 years; 59 men) with schizophrenia or schizoaffective disorder and 87 healthy controls (mean [

82 0) sibling pair studies of schizophrenia and schizoaffective disorder and a comparable study of bipol

83 psychiatric disorders, mainly schizophrenia, schizoaffective disorder and bipolar disorder.

84 individuals diagnosed with schizophrenia or schizoaffective disorder and in 197 healthy comparison s

85 individuals diagnosed with schizophrenia or schizoaffective disorder and in 197 healthy comparison s

86 men comorbid for DSM-III-R schizophrenia or schizoaffective disorder and lifetime alcohol abuse or d

87 d lifetime rates were found in patients with schizoaffective disorder and major depression with psych

88 ants included 56 women with schizophrenia or schizoaffective disorder and marked symptom severity des

89 ction from 36 subjects with schizophrenia or schizoaffective disorder and matched normal comparison s

90 Twenty-four patients with schizophrenia or schizoaffective disorder and medication-resistant AHs we

91 atients with first-episode schizophrenia and schizoaffective disorder and potential predictors of res

92 who met DSM-IV criteria for schizophrenia or schizoaffective disorder and retrospective and prospecti

93 A boundary between schizoaffective disorder and schizophrenia was not obser

94 h diagnoses of bipolar disorder, depression, schizoaffective disorder and schizophrenia).

95 met DSM-III-R criteria for schizophrenia or schizoaffective disorder and their co-twins without psyc

96 viduals with DSM-IV-defined schizophrenia or schizoaffective disorder and their mothers underwent a 4

97 o overlapping groups of patients: those with schizoaffective disorder and those with schizophrenia an

98 Affairs (VA) system who had schizophrenia or schizoaffective disorder and who had been hospitalized w

99 nsider 166 persons who have schizophrenia or schizoaffective disorder and who have had either their g

100 mple included 1,870 cases (schizophrenia and schizoaffective disorder) and 2,002 screened comparison

101 SZ (including a subgroup diagnosed as having schizoaffective disorder) and 26 age-matched and sex-mat

102 bipolar disorder with psychotic features, or schizoaffective disorder, and 10,195 population control

103 h psychosis (146 with schizophrenia, 90 with schizoaffective disorder, and 115 with psychotic bipolar

104 with schizophrenia, 106 of individuals with schizoaffective disorder, and 129 of individuals with ps

105 tients with schizophrenia, 103 patients with schizoaffective disorder, and 129 patients with psychoti

106 nts met DSM-IV criteria for schizophrenia or schizoaffective disorder, and 21 nonpsychiatric voluntee

107 atients with schizophrenia, 32 patients with schizoaffective disorder, and 40 patients with bipolar d

108 ely 65% of participants had schizophrenia or schizoaffective disorder, and 85.5% were receiving conco

109 Schizophrenia, schizoaffective disorder, and bipolar disorder are commo

110 collected on individuals with schizophrenia, schizoaffective disorder, and bipolar disorder with psyc

111 nd exon 9 are associated with schizophrenia, schizoaffective disorder, and bipolar disorder.

112 nical phenotype of psychosis (schizophrenia, schizoaffective disorder, and bipolar I disorder with ps

113 People with schizophrenia, schizoaffective disorder, and bipolar illness share clin

114 Heritability estimates for schizophrenia, schizoaffective disorder, and mania were substantial and

115 sychotic disorders (including schizophrenia, schizoaffective disorder, and psychotic bipolar disorder

116 bipolar I, bipolar II with major depression, schizoaffective disorder, and recurrent unipolar disorde

117 bipolar disorder, major depressive disorder, schizoaffective disorder, and schizophrenia) in male par

118 ntal illness (defined here as schizophrenia, schizoaffective disorders, and bipolar affective disorde

119 nergic mechanisms to treat schizophrenia and schizoaffective disorder appears indicated.

120 Bipolar, schizophrenia, and schizoaffective disorders are common, highly heritable p

121 Established nosology identifies schizoaffective disorder as a distinct category with bou

122 assess the rationale for the continuation of schizoaffective disorder as a legitimate diagnostic cate

123 were diagnosed with either schizophrenia or schizoaffective disorder as defined by the DSM-IV.

124 me, however, have questioned the validity of schizoaffective disorder as separate from psychotic mood

125 probands (63 with schizophrenia and 12 with schizoaffective disorder), ascertained so as to be repre

126 probands (60 with schizophrenia and 12 with schizoaffective disorder, ascertained so as to be repres

127 meeting DSM-IV criteria for schizophrenia or schizoaffective disorder, assessed during acute admissio

128 attempts in patients with schizophrenia and schizoaffective disorder at high risk for suicide.

129 mately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximat

130 and three psychotic disorders--schizophrenia/schizoaffective disorder, bipolar disorder with psychosi

131 ss as a clinical diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or other psy

132 9), bipolar disorder (DSM-IV-TR) (N=40), and schizoaffective disorder, bipolar type (N=18).

133 probands with bipolar I disorder (N=192) and schizoaffective disorder, bipolar type, (N=11) were incl

134 bipolar I disorder; bipolar II disorder; or schizoaffective disorder, bipolar type, according to DSM

135 ion to antipsychotic action in patients with schizoaffective disorder, bipolar type, and bipolar I di

136 nd bipolar disorder and parses patients with schizoaffective disorder, bipolar type, into two subgrou

137 d aim was to determine whether subjects with schizoaffective disorder, bipolar type, were neurophysio

138 ive disorder and a sibling with bipolar I or schizoaffective disorder, bipolar type.

139 is of a major affective disorder (BP type I; schizoaffective disorder, bipolar type; BP type II; or m

140 nts with either bipolar disorder (N = 10) or schizoaffective disorder-bipolar subtype (N = 15) for wh

141 models (ASMs) were considered: ASM1 (BPI and schizoaffective disorder, BP cases (SABP) only), ASM2 (A

142 arrow phenotype psychosis (schizophrenia and schizoaffective disorder), broad psychosis, and control

143 RNA levels were 13.6% lower in subjects with schizoaffective disorder but did not differ in subjects

144 dysregulation of calreticulin homeostasis in schizoaffective disorder by both genetic and functional

145 SZ: OR = 2.40, p = 1.3 x 10(-4); SZ, BD, and schizoaffective disorder combined: OR = 1.87, p = 8 x 10

146 Twenty-six patients with schizophrenia and schizoaffective disorder completed a task requiring alte

147 The diagnosis of schizoaffective disorder depends on the disease specific

148 and in patients with schizophrenia (N=12) or schizoaffective disorder, depressed type (N=4), during a

149 nostic Criteria major depressive disorder or schizoaffective disorder, depressed type, entered a long

150 atients with a diagnosis of schizophrenia or schizoaffective disorder, depressed type.

151 A 40-yr-old woman with a diagnosis of schizoaffective disorder developed catatonia in the cont

152 rge among 151 patients with schizophrenia or schizoaffective disorder diagnosed according to Research

153 Cases with diagnoses of schizophrenia or schizoaffective disorder (DSM-IIIR criteria) were consid

154 hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blin

155 The patients with schizophrenia or schizoaffective disorder exhibited less accuracy and spe

156 henotypes for probands with schizophrenia or schizoaffective disorder (extensive neocortical or subco

157 ID1) met this criterion for schizophrenia or schizoaffective disorder; five replicate previous associ

158 lar affective disorder (from 84% to 43%) and schizoaffective disorder (from 100% to 53%).

159 The schizophrenia or schizoaffective disorder group exhibited decreased power

160 The schizoaffective disorder group was split, with six subje

161 the schizophrenia, simple schizophrenia, and schizoaffective disorder group were inversely related (b

162 The diagnosis of schizoaffective disorder has long maintained an uncertai

163 n this mutation in the calreticulin gene and schizoaffective disorder has remained speculative.

164 ents with clinically stable schizophrenia or schizoaffective disorder have a lower risk of relapse if

165 atients with first-episode schizophrenia and schizoaffective disorder have high rates of response to

166 However, because most prior studies of schizoaffective disorder have only evaluated differences

167 2q11 microdeletions develop schizophrenia or schizoaffective disorder in adolescence and adulthood.

168 iated with the diagnosis of schizophrenia or schizoaffective disorder in the white subset of the stud

169 revious studies, these findings suggest that schizoaffective disorder is associated with lower levels

170 uggest that negative affect in schizophrenia/schizoaffective disorder is associated-directly or indir

171 s of rarity between them and suggesting that schizoaffective disorder is not a separate, 'bona-fide'

172 r, the interrater reliability for diagnosing schizoaffective disorder is very low.

173 Patients diagnosed with schizoaffective disorder likely suffer from a psychotic

174 Research Diagnostic Criteria schizophrenia, schizoaffective disorder, mania, DSM-III-R schizophrenia

175 y greater from bipolar disorder (z=-0.77) to schizoaffective disorder (manic z=-1.08; depressed z=-1.

176 (N=293), psychotic bipolar disorder (N=227), schizoaffective disorder (manic, N=110; depressed, N=55)

177 -six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and

178 Contrary to earlier formulations, schizoaffective disorder may be a more severe form of il

179 that hippocampal volume in schizophrenia or schizoaffective disorder may be linked to time of diseas

180 These results suggest that schizoaffective disorder may possess distinct features.

181 outpatients diagnosed with schizophrenia or schizoaffective disorder (mean [SD] age, 46 [11] years;

182 In the subjects with schizoaffective disorder, mean GAD65 protein levels were

183 7); schizophrenia, simple schizophrenia, and schizoaffective disorder (n = 178); and all nonaffective

184 Patients with schizophrenia (N = 52) or schizoaffective disorder (N = 25) were evaluated for the

185 eting criteria for schizophrenia (n = 19) or schizoaffective disorder (n = 7) and 26 healthy controls

186 ollow-Up Study with schizophrenia (N = 187), schizoaffective disorder (N = 87), schizophreniform diso

187 s in their first episode of schizophrenia or schizoaffective disorder (N=118) were assessed at baseli

188 cording to DSM-IV as having schizophrenia or schizoaffective disorder (N=155), bipolar disorder with

189 nth follow-up to patients with schizophrenia/schizoaffective disorder (N=225), bipolar disorder with

190 e offspring of mothers with schizophrenia or schizoaffective disorder (N=26) and matched comparison m

191 ed for nonpsychotic bipolar disorder (N=68), schizoaffective disorder (N=31), or schizophrenia (N=536

192 Adults with schizophrenia or schizoaffective disorder (N=481) were randomly assigned

193 icated patients with schizophrenia (N=61) or schizoaffective disorder (N=6).

194 ection sites, patients with schizophrenia or schizoaffective disorder (N=610), their biological relat

195 psychotic disorders (schizophrenia, n = 219; schizoaffective disorder, n = 142; and psychotic bipolar

196 7 schizophrenia cases (schizophrenia, N=630; schizoaffective disorder, N=147) with maternal sera avai

197 Furthermore, patients with a diagnosis of schizoaffective disorder or a history of at least one ma

198 t of other variables, such as a diagnosis of schizoaffective disorder or medication use at the time o

199 For acute exacerbations of schizoaffective disorder or of schizophrenia with mood s

200 trial included patients with schizophrenia, schizoaffective disorder, or a mood disorder who had mod

201 d first-degree relatives with schizophrenia, schizoaffective disorder, or bipolar disorder.

202 nths; a clinical diagnosis of schizophrenia, schizoaffective disorder, or delusional disorder; and a

203 participants with underlying schizophrenia, schizoaffective disorder, or mood disorder.

204 of patients hospitalized for schizophrenia, schizoaffective disorder, or nonpsychotic bipolar disord

205 1239 cases with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder;

206 ited 933 stable probands with schizophrenia, schizoaffective disorder, or psychotic bipolar I disorde

207 ients with a first episode of schizophrenia, schizoaffective disorder, or schizophreniform disorder (

208 had a DSM-III-R diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder a

209 who were later diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder,

210 ht outpatients with chronic schizophrenia or schizoaffective disorder over 16 weeks.

211 morbidity, and diagnosis of schizophrenia or schizoaffective disorder (p<0.01 for all contrasts).

212 al regions were limited to schizophrenia and schizoaffective disorders (P < .001).

213 One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, doub

214 tivity (rsfMRI) approach in 84 schizophrenia/schizoaffective disorder patients and 66 healthy compari

215 positive psychotic symptoms in schizophrenia/schizoaffective disorder patients at 24 months suggests

216 ed (125 SZ, 120 bipolar disorder [BD] and 36 schizoaffective disorder patients vs. 467 unaffected adu

217 than the other two groups, and schizophrenia/schizoaffective disorder patients with baseline panic sy

218 Finally, within the schizophrenic/schizoaffective disorder patients, smaller hippocampal v

219 Subjects with schizoaffective disorder performed significantly worse t

220 esponse were diagnosis (schizophrenia versus schizoaffective disorder), premorbid functioning, durati

221 SZ probands, n = 224; PBD probands, n = 190; schizoaffective disorder probands, n = 142; unaffected r

222 riptome signatures are not characteristic of schizoaffective disorder, providing a potential molecula

223 ome among outpatients with schizophrenia and schizoaffective disorder receiving clozapine with a matc

224 ple of 162 outpatients with schizophrenia or schizoaffective disorder recruited from four sites.

225 generally better preserved in patients with schizoaffective disorder relative to patients with schiz

226 relatives, n = 195; PBD relatives, n = 175; schizoaffective disorder relatives, n = 113]; control su

227 r disorder (RR, 0.42; 95% CI, 0.17-0.69) and schizoaffective disorder (RR, 0.44; 95% CI, 0.11-0.79) c

228 a superimposed mood syndrome [SZ+; N = 224], schizoaffective disorder [SAD; N = 129] and bipolar I di

229 netic, reveals multiple similarities between schizoaffective disorder, schizophrenia and psychotic bi

230 Inpatient diagnoses of bipolar disorder, schizoaffective disorder, schizophrenia, and other nonaf

231 present or present to a lesser degree in the schizoaffective disorder subjects (diagnosis of schizoaf

232 in a live cohort of psychosis (schizophrenia/schizoaffective disorder) subjects.

233 (SZ), psychotic bipolar disorder (PBD), and schizoaffective disorder; their first-degree relatives;

234 iously reported linkage of schizophrenia and schizoaffective disorder to 13q32-34 in the European des

235 btained in 70 patients with schizophrenia or schizoaffective disorder to determine their response to

236 cal and biological features of patients with schizoaffective disorder to patients with related disord

237 able condition with chronic schizophrenia or schizoaffective disorder to receive treatment with flexi

238 we have also found linkage of schizophrenia/schizoaffective disorder to this same chromosomal region

239 patients with early-onset schizophrenia and schizoaffective disorder to treatment with either olanza

240 schizophrenia, schizophreniform disorder, or schizoaffective disorder treated with olanzapine (N = 70

241 Schizoaffective disorder unifies schizophrenia and bipol

242 In adults with schizophrenia or schizoaffective disorder, use of paliperidone palmitate

243 sensus diagnosis of schizophrenia (including schizoaffective disorder) using DSM-III or DSM-IV criter

244 Schizoaffective disorder was associated with low emotion

245 opathology in patients with schizophrenia or schizoaffective disorder was examined before and after t

246 and 63 female patients with schizophrenia or schizoaffective disorder was extensively studied and com

247 for the phenotype of DSM-IV schizophrenia or schizoaffective disorder was found in a region on chromo

248 Schizoaffective disorder was named as a compromise diagn

249 izoaffective disorder subjects (diagnosis of schizoaffective disorder was the most significant covari

250 rty-three outpatients with schizophrenia and schizoaffective disorder were categorized into deficit a

251 schizophrenia, schizophreniform disorder, or schizoaffective disorder were evaluated during their fir

252 Thirty patients with schizophrenia or schizoaffective disorder were investigated.

253 The characteristics of schizoaffective disorder were more often similar to schi

254 mRNA and protein levels within subjects with schizoaffective disorder were not attributable to factor

255 y-five patients with DSM-IV schizophrenia or schizoaffective disorder were randomly assigned for 9 mo

256 Sixty-nine people with schizophrenia or schizoaffective disorder were randomly assigned to 36 se

257 Sixty-five patients with schizophrenia or schizoaffective disorder were randomly assigned to NET p

258 who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to recei

259 outpatients with DSM-III-R schizophrenia or schizoaffective disorder were randomly assigned to recei

260 Fifty outpatients with schizophrenia or schizoaffective disorder were randomly assigned to recei

261 7) outpatients with chronic schizophrenia or schizoaffective disorder were randomly assigned to recei

262 lly stable outpatients with schizophrenia or schizoaffective disorder were randomly assigned to train

263 total of 181 patients with schizophrenia or schizoaffective disorder were recruited from three clini

264 SFs of the individuals with schizophrenia or schizoaffective disorder were related to those of the hu

265 n) with DSM-IV diagnoses of schizophrenia or schizoaffective disorder were selected to form two group

266 ia for treatment-refractory schizophrenia or schizoaffective disorder were studied.

267 cing their first episode of schizophrenia or schizoaffective disorder were treated first with clozapi

268 Individuals with schizophrenia or schizoaffective disorders were included as cases.

269 e (as a part of major depressive disorder or schizoaffective disorder) were at a greater risk for sui

270 ved a research diagnosis of schizophrenia or schizoaffective disorder, whereas 44% of patients with n

271 The diagnosis of schizoaffective disorder, which can result in substandar

272 tics of 52 individuals with schizophrenia or schizoaffective disorder who had attempted suicide with

273 ose of 104 individuals with schizophrenia or schizoaffective disorder who had not made a suicide atte

274 tients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despi

275 cessation in patients with schizophrenia or schizoaffective disorder who were also treated with the

276 were adults diagnosed with schizophrenia or schizoaffective disorder who were clinically assessed to

277 ts were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a

278 lve patients with DSM-IV bipolar disorder or schizoaffective disorder who were clinically stable whil

279 ects were 322 patients with schizophrenia or schizoaffective disorder who were consecutively admitted

280 cing their first episode of schizophrenia or schizoaffective disorder who were given fluphenazine as

281 treatment in patients with schizophrenia and schizoaffective disorder who were hospitalized or at hig

282 d fifty-seven patients with schizophrenia or schizoaffective disorder who were inpatients at four hos

283 ly assaultive subjects with schizophrenia or schizoaffective disorder who were inpatients in state ps

284 Thirty patients with schizophrenia or schizoaffective disorder who were receiving clozapine mo

285 ients with the diagnoses of schizophrenia or schizoaffective disorder who were treated with risperido

286 spectrum disorders (mostly schizophrenia and schizoaffective disorder) who had available second-trime

287 re mental illness (46% with schizophrenia or schizoaffective disorder) who had not obtained or kept c

288 Patients with schizophrenia or schizoaffective disorder with a body mass index >/= 27 a

289 ded schizophrenia, simple schizophrenia, and schizoaffective disorder with poor outcome.

290 severity continuum (schizophrenia worse than schizoaffective disorder worse than bipolar psychosis);